Vir Financial Statements From 2010 to 2025

VIR Stock  USD 7.01  0.14  1.96%   
Vir Biotechnology financial statements provide useful quarterly and yearly information to potential Vir Biotechnology investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Vir Biotechnology financial statements helps investors assess Vir Biotechnology's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Vir Biotechnology's valuation are summarized below:
Gross Profit
-404.4 M
Market Capitalization
980.6 M
Enterprise Value Revenue
2.7172
Revenue
74.2 M
Earnings Share
(3.83)
There are over one hundred nineteen available fundamental trend indicators for Vir Biotechnology, which can be analyzed over time and compared to other ratios. Investors and active traders are advised to double-check Vir Biotechnology's current fundamental performance against the performance between 2010 and 2025 to make sure the trends are evolving in the right direction. As of 03/18/2025, Market Cap is likely to grow to about 1.8 B, while Enterprise Value is likely to drop slightly above 739 M.

Vir Biotechnology Total Revenue

70.49 Million

Check Vir Biotechnology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Vir Biotechnology's main balance sheet or income statement drivers, such as Net Interest Income of 75.4 M, Interest Income of 75.4 M or Discontinued Operations of 0.0, as well as many indicators such as Price To Sales Ratio of 12.8, Dividend Yield of 0.0 or PTB Ratio of 0.91. Vir financial statements analysis is a perfect complement when working with Vir Biotechnology Valuation or Volatility modules.
  
Check out the analysis of Vir Biotechnology Correlation against competitors.
To learn how to invest in Vir Stock, please use our How to Invest in Vir Biotechnology guide.

Vir Biotechnology Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets1.4 B1.4 B817.3 M
Slightly volatile
Other Current Liabilities142.7 M101.9 M77.1 M
Slightly volatile
Total Current Liabilities186.7 M119.7 M102 M
Slightly volatile
Other Liabilities107.8 M102.6 M39.9 M
Slightly volatile
Property Plant And Equipment Net99.3 M122.9 M53.6 M
Slightly volatile
Accounts Payable6.4 M5.1 M5.5 M
Slightly volatile
Cash348.1 M312.3 M262.2 M
Slightly volatile
Non Current Assets Total240.6 M356.4 M150.3 M
Slightly volatile
Other Assets1.091.158.1 M
Pretty Stable
Cash And Short Term Investments966.6 M990.4 M582 M
Slightly volatile
Good Will13.5 M15.2 M16.6 M
Slightly volatile
Common Stock Total Equity8.6 K14.9 KK
Slightly volatile
Common Stock Shares Outstanding131.9 M136.2 M110.6 M
Slightly volatile
Liabilities And Stockholders Equity1.4 B1.4 B817.3 M
Slightly volatile
Non Current Liabilities Total144.7 M128.8 M234.3 M
Slightly volatile
Capital Surpluse1.9 B1.8 B667.8 M
Slightly volatile
Other Current Assets60.1 M52.1 M33 M
Slightly volatile
Other Stockholder Equity1.2 B1.9 B623.3 M
Slightly volatile
Total Liabilities385.7 M248.4 M339.6 M
Pretty Stable
Property Plant And Equipment Gross100.5 M159.6 M54.2 M
Slightly volatile
Total Current Assets1.1 BB667 M
Slightly volatile
Non Current Liabilities Other36.7 M38.6 M23.5 M
Slightly volatile
Net Working Capital940.5 M922.8 M565 M
Slightly volatile
Intangible Assets7.7 M8.1 M31.1 M
Slightly volatile
Common Stock10.9 K14 K6.1 K
Slightly volatile
Property Plant Equipment227.2 M216.4 M64.9 M
Slightly volatile
Current Deferred Revenue12 M12.6 M18.4 M
Slightly volatile
Capital Stock12.3 K14 K6.1 K
Slightly volatile
Short and Long Term Debt Total99.7 M90.1 M40.9 M
Slightly volatile
Net Receivables9.9 M10.4 M53.3 M
Pretty Stable

Vir Biotechnology Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Net Interest Income75.4 M71.8 M17.3 M
Slightly volatile
Interest Income75.4 M71.8 M17.3 M
Slightly volatile
Depreciation And Amortization10.3 M14.6 M5.5 M
Slightly volatile
Selling General Administrative106.5 M119 M64.6 M
Slightly volatile
Total Revenue70.5 M74.2 M186.1 M
Slightly volatile
Other Operating Expenses494.8 M661.4 M291.6 M
Slightly volatile
Research Development362 M506.5 M214.5 M
Slightly volatile
Cost Of Revenue802.8 K845 K78.8 M
Very volatile
Total Operating Expenses465.2 M660.5 M276.2 M
Slightly volatile
Reconciled Depreciation7.9 M14.6 M4.3 M
Slightly volatile

Vir Biotechnology Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation58 M78.5 M32.1 M
Slightly volatile
Begin Period Cash Flow320.3 M261.3 M171.8 M
Slightly volatile
Depreciation21 M20 M5.6 M
Slightly volatile
Capital Expenditures6.9 M7.3 M10.7 M
Slightly volatile
Total Cash From Financing Activities4.2 M4.4 M207.8 M
Slightly volatile
End Period Cash Flow362.2 M318.7 M269.9 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio12.813.47694.8 K
Slightly volatile
Days Sales Outstanding208234255
Slightly volatile
Stock Based Compensation To Revenue1.01.057317.4211
Slightly volatile
Capex To Depreciation0.350.36594.5338
Slightly volatile
EV To Sales9.9610.48264.1 K
Slightly volatile
Inventory Turnover6.136.97.5204
Slightly volatile
Days Of Inventory On Hand38.142.8646.7317
Slightly volatile
Payables Turnover0.160.166314.7425
Very volatile
Sales General And Administrative To Revenue1.151.2178.6091
Slightly volatile
Research And Ddevelopement To Revenue6.486.8257232
Slightly volatile
Capex To Revenue0.09350.098410.6147
Slightly volatile
Cash Per Share5.497.2694.6218
Slightly volatile
Interest Coverage3.644.094.4632
Slightly volatile
Days Payables Outstanding2.3 K2.2 K354
Slightly volatile
Intangibles To Total Assets0.0170.01790.1386
Slightly volatile
Current Ratio8.298.711711.0524
Slightly volatile
Receivables Turnover1.131.271.3804
Slightly volatile
Capex Per Share0.05090.05360.0872
Slightly volatile
Revenue Per Share0.520.54461.4117
Slightly volatile
Interest Debt Per Share0.640.66160.4442
Slightly volatile
Debt To Assets0.04220.06440.0522
Very volatile
Graham Number27.5233.3332.261
Pretty Stable
Operating Cycle246276301
Slightly volatile
Days Of Payables Outstanding2.3 K2.2 K354
Slightly volatile
Ebt Per Ebit1.190.89091.0491
Pretty Stable
Long Term Debt To Capitalization0.05820.06540.0713
Slightly volatile
Quick Ratio8.288.711711.0502
Slightly volatile
Net Income Per E B T1.030.99780.9105
Slightly volatile
Cash Ratio4.022.61018.6875
Slightly volatile
Days Of Inventory Outstanding38.142.8646.7317
Slightly volatile
Days Of Sales Outstanding208234255
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.21.01641.0739
Pretty Stable
Fixed Asset Turnover0.570.6041.2272
Slightly volatile
Debt Ratio0.04220.06440.0522
Very volatile
Price Sales Ratio12.813.47694.8 K
Slightly volatile
Asset Turnover0.05040.0530.0845
Slightly volatile

Vir Biotechnology Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap1.8 BB1.9 B
Slightly volatile
Enterprise Value739 M777.9 M1.6 B
Pretty Stable

Vir Fundamental Market Drivers

Forward Price Earnings4.3611
Cash And Short Term Investments990.4 M

Vir Upcoming Events

22nd of February 2024
Upcoming Quarterly Report
View
2nd of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
22nd of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Vir Biotechnology Financial Statements

Vir Biotechnology shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Vir Biotechnology investors may analyze each financial statement separately, they are all interrelated. The changes in Vir Biotechnology's assets and liabilities, for example, are also reflected in the revenues and expenses on on Vir Biotechnology's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue12.6 M12 M
Total Revenue74.2 M70.5 M
Cost Of Revenue845 K802.8 K
Stock Based Compensation To Revenue 1.06  1.00 
Sales General And Administrative To Revenue 1.21  1.15 
Research And Ddevelopement To Revenue 6.83  6.48 
Capex To Revenue 0.10  0.09 
Revenue Per Share 0.54  0.52 
Ebit Per Revenue(7.91)(8.31)

Pair Trading with Vir Biotechnology

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Vir Biotechnology position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Vir Biotechnology will appreciate offsetting losses from the drop in the long position's value.

Moving together with Vir Stock

  0.67A Agilent TechnologiesPairCorr

Moving against Vir Stock

  0.57DSGN Design TherapeuticsPairCorr
  0.38DVAX Dynavax TechnologiesPairCorr
The ability to find closely correlated positions to Vir Biotechnology could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Vir Biotechnology when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Vir Biotechnology - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Vir Biotechnology to buy it.
The correlation of Vir Biotechnology is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Vir Biotechnology moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Vir Biotechnology moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Vir Biotechnology can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for Vir Stock Analysis

When running Vir Biotechnology's price analysis, check to measure Vir Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vir Biotechnology is operating at the current time. Most of Vir Biotechnology's value examination focuses on studying past and present price action to predict the probability of Vir Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vir Biotechnology's price. Additionally, you may evaluate how the addition of Vir Biotechnology to your portfolios can decrease your overall portfolio volatility.